...
首页> 外文期刊>The Canadian journal of hospital pharmacy. >Management of Supratherapeutic International Normalized Ratio without Bleeding after Warfarin Use: An Evaluation of Vitamin K Administration (SUPRA-WAR-K Study)
【24h】

Management of Supratherapeutic International Normalized Ratio without Bleeding after Warfarin Use: An Evaluation of Vitamin K Administration (SUPRA-WAR-K Study)

机译:华法林使用后,在不出血的情况下进行辛艾拉等国际规范化的管理:对维生素K管理的评价(Supra-War-K研究)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: For patients with supratherapeutic international normalized ratio (INR) and no evidence of bleeding, the 2012 guidelines of the American College of Chest Physicians discourage administration of vitamin K. At the study hospital, it was observed that vitamin K was frequently prescribed for patients with INR of 4.5 or higher and no bleeding. Objectives: To compare efficacy and safety outcomes between holding warfarin alone and holding warfarin with administration of vitamin K and to compare these outcomes among various doses and routes of vitamin K administration in non-critical care inpatients experiencing supratherapeutic INR without evidence of bleeding. Methods: This single-centre retrospective chart review involved non-critical care inpatients with supratherapeutic INR (4.5-8.9) without evidence of bleeding. The primary outcomes were the change in INR 1 day after implementation of supratherapeutic INR management and the time to reach INR less than 3.0. The secondary outcomes were length of stay, frequency of warfarin resistance, incidence and duration of bridging anticoagulation, incidence of thromboembolism and major bleeding, and death. Results: Regardless of vitamin K dose, the administration of vitamin K combined with holding warfarin, relative to holding warfarin alone, was associated with a greater INR decrease 1 day after the intervention (mean ± standard deviation-3.2 ± 1.9 versus- 0.9 ± 1.0,p< 0.001) and ashorter time to reach INR below 3.0 (1.9 ± 1.0 days versus 2.6 ± 1.4 days, p = 0.003). No statistically significant differences in any other outcomes were observed. Conclusions: In hospitalized non-critical care patients with INR between 4.5 and 8.9 without evidence of bleeding, the combination of holding warfarin and administering vitamin K was associated with greater and faster decreases in INR than holding warfarin alone. No significant differences were found in clinically important outcomes. The practice of administering vitamin K in this population warrants further study and re-evaluation.
机译:背景:对于具有超治疗性国际标准化比值(INR)且无出血证据的患者,美国胸科医师学会2012年的指南不鼓励服用维生素K。在研究医院,观察到INR为4.5或更高且无出血的患者经常服用维生素K。目的:比较单独服用华法林和服用华法林并服用维生素K的疗效和安全性结果,并比较服用不同剂量和途径的维生素K对无出血证据的非重症监护住院患者发生超治疗性INR的疗效和安全性。方法:这项单中心回顾性图表回顾性研究涉及非危重病住院患者,其超治疗性INR(4.5-8.9)无出血迹象。主要结果是实施超治疗性INR管理后1天INR的变化,以及达到INR小于3.0的时间。次要转归是住院时间、华法林耐药频率、桥连抗凝的发生率和持续时间、血栓栓塞和大出血的发生率以及死亡。结果:无论维生素K的剂量如何,与单独服用华法林相比,服用维生素K联合服用华法林,干预后1天的INR下降幅度更大(平均值±标准偏差-3.2±1.9对-0.9±1.0,p<0.001),INR下降幅度更大(1.9±1.0天对2.6±1.4天,p=0.003)。未观察到任何其他结果的统计学显著差异。结论:在INR在4.5到8.9之间且无出血迹象的住院非危重病患者中,与单独服用华法林相比,服用华法林和服用维生素K的组合与INR的降低更大更快相关。在临床重要结果方面未发现显著差异。该人群服用维生素K的实践值得进一步研究和重新评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号